Absci CORP

Absci Corporation has priced an underwritten public offering of 13,495,277 shares of common stock at $7.41 per share to raise approximately $100 million.

Absci Corporation announced favorable interim Phase 1 safety and pharmacokinetic results for ABS-201, its AI-designed antibody targeting hair loss and endometriosis.

Absci Corporation stockholders re-elected Class II directors and ratified the appointment of Ernst & Young LLP as auditors.

Absci Corporation announced its first quarter 2026 financial and operating results, highlighting progress in its ABS-201 clinical trials for androgenetic alopecia and endometriosis, and the addition of ABS-202 to its pipeline.

Absci Corporation announced its fourth quarter and full year 2025 financial results, highlighted by clinical progress for ABS-201 in hair loss and endometriosis, and advancements in its AI-driven drug discovery platform.

Absci Corporation announced the appointment of Ransi Somaratne, M.D., as Chief Medical Officer, the retirement of Chief Innovation Officer Andreas Busch, and updated director and officer indemnification agreements.

Absci Corporation's Q2 2026 filing reveals a widening net loss and increased R&D expenses, though positive interim data for its lead candidate ABS-201 offers a glimmer of progress.

Absci Corporation reports increased net losses and decreased partner revenue in Q3 2025, while advancing its AI drug creation platform and seeking a partner for its lead candidate ABS-101.

Absci Corporation reported increased net losses and decreased revenue for Q2 2025, driven by higher research and development expenses, but bolstered its liquidity with over $60 million in post-period capital raises.

Absci Corporation's Q1 2025 results show increased revenue from partner programs and ongoing clinical development of ABS-101 for Inflammatory Bowel Disease.

Absci Corporation's Q3 2024 results show increased revenue and a reduced net loss compared to the previous quarter, alongside advancements in their AI-driven drug creation platform.

Absci Corporation's Q2 2024 results show a decrease in technology development revenue compared to the same period last year, while the company continues to invest in research and development.

Absci Corporation reported a wider net loss and decreased revenue for 2025, while advancing its lead antibody therapeutic, ABS-201, into clinical trials for androgenetic alopecia and endometriosis.

Absci Corporation's 2024 10-K filing highlights its focus on AI-driven antibody therapeutics, partnered programs, and internal pipeline development, despite incurring a net loss of $103.1 million.

Absci Corporation has established a 2023 Inducement Plan to grant equity awards to prospective officers and employees, aiming to align their interests with the company's success.

Ransi Mudalinayake Somaratne, CMO, Head of R&D of Absci Corp, reported multiple transactions in common stock on March 3, 2026.

Director Mary T. Szela of Absci Corp reported an open market purchase of 12,900 common shares.

Absci Corp CEO Sean McClain reported a transaction involving the withholding of shares for tax obligations related to performance-based RSUs.

Director Mary T. Szela receives corrected equity grant of 8,400 RSUs and 33,200 stock options.

Director Karen McGinnis of Absci Corp acquired 10,100 shares of common stock through Restricted Stock Units and was granted an option to purchase 39,800 shares.

Absci Corp director Mary T. Szela was granted 10,100 restricted stock units and 39,800 stock options as part of her board compensation.

ABSCI Corporation has filed a definitive proxy statement with the SEC, indicating upcoming corporate actions requiring shareholder votes.

Absci leverages generative AI to accelerate biologics creation, advancing internal pipeline and strategic partnerships towards becoming a clinical-stage biotech company.

ABSCI Corporation has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.

Absci Corporation's 2024 Annual Meeting highlights the company's AI-driven approach to drug discovery, aiming to accelerate therapeutic development and improve patient outcomes.

Redmile Group, LLC and Jeremy C. Green have filed an amendment to their Schedule 13D, reporting the sale of 645,867 shares of Absci Corporation common stock on April 10, 2026, reducing their beneficial ownership to 4.9%.

Redmile Group, LLC and Jeremy C. Green reported a decrease in their beneficial ownership of Absci Corporation common stock to 5.4% due to an increase in the issuer's outstanding shares.

Redmile Group, LLC and its managing member Jeremy C. Green updated their beneficial ownership in Absci Corporation to 6.5%, while noting the resignation of Amrit Nagpal from Absci's Board of Directors.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Absci Corp common stock following an internal realignment.

The Vanguard Group has reported a 5.26% beneficial ownership stake in Absci Corp, holding over 7.9 million common shares.

Sean McClain, a key insider at Absci Corporation, has increased his beneficial ownership to 7.2% of the common stock, as disclosed in an amended Schedule 13G filing.

The Vanguard Group disclosed a 4.87% beneficial ownership in Absci Corp common stock, affirming a passive investment position.

The Vanguard Group has reported a passive beneficial ownership of 5.05% in Absci Corp, holding over 6.45 million shares of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 6.5% of ABSCI CORP's common stock as of June 30, 2025.